Table 1 Clinical and pathologic variables of the Yonsei cohort as stratified by the four genetic subtypes.
From: Development and validation of a prognostic and predictive 32-gene signature for gastric cancer
Characteristics | Group 1 (Black) | Group 2 (Green) | Group 3 (Blue) | Group 4 (Red) | Total | P valuea |
|---|---|---|---|---|---|---|
N | 114 (20.1%) | 129 (22.8%) | 162 (28.6%) | 162 (28.6%) | 567 | |
Age | ||||||
≤60 years | 43 (37.7%) | 53 (41.1%) | 90 (55.6%) | 89 (54.9%) | 275 (48.5%) | 0.003 |
>60 years | 71 (62.3%) | 76 (58.9%) | 72 (44.4%) | 73 (45.1%) | 292 (51.5%) | |
Sex | ||||||
Male | 77 (67.5%) | 93 (72.1%) | 114 (70.4%) | 102 (63.0%) | 386 (68.1%) | 0.346 |
Female | 37 (32.5%) | 36 (27.9%) | 48 (29.6%) | 60 (37.0%) | 181 (31.9%) | |
Stage | ||||||
I | 10 (8.8%) | 3 (2.3%) | 7 (4.3%) | 1 (0.6%) | 21 (3.7%) | 0.021 |
II | 33 (28.9%) | 36 (27.9%) | 33 (20.4%) | 45 (27.8%) | 147 (25.9%) | |
III | 69 (60.5%) | 87 (67.4%) | 115 (71.0%) | 108 (66.7%) | 379 (66.8%) | |
IV | 2 (1.8%) | 3 (2.3%) | 7 (4.3%) | 8 (4.9%) | 20 (3.5%) | |
Tumor location | ||||||
Antrum | 60 (52.6%) | 83 (64.3%) | 85 (52.5%) | 88 (54.3%) | 316 (55.7%) | 0.338 |
Body | 38 (33.3%) | 33 (25.6%) | 57 (35.2%) | 54 (33.3%) | 182 (32.1%) | |
Cardia | 4 (3.5%) | 11 (8.5%) | 16 (9.9%) | 13 (8.0%) | 44 (7.8%) | |
Whole | 1 (0.9%) | 0 (0.0%) | 2 (1.2%) | 3 (1.9%) | 6 (1.1%) | |
Missing | 11 (9.6%) | 2 (1.6%) | 2 (1.2%) | 4 (2.5%) | 19 (3.4%) | |
Lauren type | ||||||
Diffuse | 21 (18.4%) | 33 (25.6%) | 55 (34.0%) | 89 (54.9%) | 198 (34.9%) | <0.001 |
Intestinal | 56 (49.1%) | 60 (46.5%) | 35 (21.6%) | 43 (26.5%) | 194 (34.2%) | |
Mixed | 6 (5.3%) | 9 (7.0%) | 4 (2.5%) | 6 (3.7%) | 25 (4.4%) | |
Other | 31 (27.2%) | 26 (20.2%) | 68 (42.0%) | 24 (14.8%) | 149 (26.3%) | |
Missing | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) | 0 (0.0%) | 1 (0.2%) | |
Lymphovascular invasion | ||||||
Positive | 57 (50.0%) | 70 (54.3%) | 65 (40.1%) | 76 (46.9%) | 268 (47.3%) | 0.094 |
Negative | 56 (49.1%) | 57 (44.2%) | 95 (58.6%) | 86 (53.1%) | 294 (51.9%) | |
Missing | 1 (0.9%) | 2 (1.6%) | 2 (1.2%) | 0 (0.0%) | 5 (0.9%) | |
Perineural invasion | ||||||
Positive | 19 (16.7%) | 17 (13.2%) | 28 (17.3%) | 63 (38.9%) | 127 (22.4%) | <0.001 |
Negative | 92 (80.7%) | 109 (84.5%) | 132 (81.5%) | 99 (61.1%) | 432 (76.2%) | |
Missing | 3 (2.6%) | 3 (2.3%) | 2 (1.2%) | 0 (0.0%) | 8 (1.4%) | |
Epstein–Barr Virus | ||||||
Positive | 4 (3.5%) | 2 (1.6%) | 7 (4.3%) | 6 (3.7%) | 19 (3.4%) | 0.568 |
Negative | 44 (38.6%) | 51 (39.5%) | 60 (37.0%) | 55 (34.0%) | 210 (37.0%) | |
Missing | 66 (57.9%) | 76 (58.9%) | 95 (58.6%) | 101 (62.3%) | 338 (59.6%) | |
Microsatellite instability | ||||||
Yes | 10 (28.6%) | 7 (14.0%) | 2 (11.8%) | 2 (2.7%) | 21 | 0.36 |
No | 25 (71.4%) | 43 (86.0%) | 15 (86.7%) | 73 (97.3%) | 156 | |
Chemotherapy receipt | ||||||
Yes | 85 (74.6%) | 104 (80.6%) | 129 (79.6%) | 135 (83.3%) | 453 (79.9%) | 0.36 |
No | 28 (24.6%) | 24 (18.6%) | 32 (19.8%) | 26 (16.0%) | 110 (19.4%) | |
Missing | 1 (0.9%) | 1 (0.8%) | 1 (0.6%) | 1 (0.6%) | 4 (0.7%) | |
